Should I buy Pfizer stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Pfizer's performance for over three years. Each month, hundreds of thousands of users in the United States rely on us to break down market trends and identify top investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Pfizer.

What is Pfizer?

How much is Pfizer stock?

The price of Pfizer stock is rising this week. As of today, Pfizer trades at $23.93, reflecting a 24-hour decrease of $0.48 (-1.97%) but a weekly gain of 5.05%. The company’s market capitalization stands at $135.72 billion, with an average three-month daily volume of 52.63 million shares.

While the stock offers a strong dividend, investors should be mindful of recent volatility and the company’s revenue transition.

Our full analysis on Pfizer stock

Having rigorously reviewed Pfizer Inc.’s latest financial results, stock behavior over the past three years, and performed a thorough cross-analysis using proprietary algorithms that aggregate fundamental metrics, technical trends, market sentiment, and peer performance, we present a targeted outlook on PFE. This integrated approach empowers a fresh perspective on a stock that has recently polarized market outlooks but retains considerable strategic weight within the healthcare and large-cap pharmaceutical landscape. So, why might Pfizer once again become a pivotal entry point for investors seeking exposure to global biopharma innovation in 2025?

Recent Performance and Market Context

Pfizer’s share price recently closed at $23.93—down by 1.97% on the latest trading day, but up 5.05% over the past week. Despite a challenging year reflected in its -14.81% six-month and -11.96% one-year performances, the stock displays signs of stabilization, holding above its 52-week low of $20.92 and well positioned from a risk-reward perspective near key long-term support zones. This recalibration period is not unique to Pfizer; much of Big Pharma navigated post-pandemic normalization and sector rotation, resulting in broad underperformance versus tech and megacap peers in 2024.

Recent events, however, have started to tip the sentiment scale. First-quarter 2025 results, published April 29, not only exceeded consensus on adjusted EPS ($0.92 vs. $0.82 in Q1 2024) but also demonstrated the effectiveness of cost-cutting initiatives—now driving an anticipated $7.7 billion in annual savings and offsetting near-term revenue declines from COVID-19 product normalization. Pfizer's management reaffirmed robust full-year 2025 guidance, which instills confidence as the company pivots from pandemic-era volatility toward a renewed base of recurring prescription and vaccine sales.

The broader healthcare sector continues to benefit from favorable macroeconomic winds: steady demand for pharmaceutical innovation, aging global populations, and increasing public investment in healthcare infrastructure. In particular, Pfizer’s diversified portfolio positions the firm to benefit as the sector enters a new innovation cycle—powered by advancements in immunology, oncology, and rare disease therapeutics.

Technical Analysis

From a technical perspective, recent market dynamics appear especially constructive for tactical investors. Pfizer is trading above its short-term moving averages (5-day SMA at $23.39 and 20-day SMA at $22.75), indicating nascent bullish momentum after a prolonged decline. Despite remaining below the 50-, 100-, and 200-day SMAs (suggesting the longer-term trend is still consolidative), the current price action reflects an emerging bull structure, with the stock having decisively bounced off its $21.91 and $21.59 support levels.

Notably, the recent 5% weekly gain and break above short-term averages, paired with tested support around $21.50, signal that Pfizer is potentially moving out of its base and into the first leg of a renewed rally. Immediate resistance is identified at $24.45 and $25.43, with a close above these levels likely drawing technical buyers and momentum funds back into the fold.

Fundamental Analysis

Pfizer’s fundamental profile remains compelling, especially in light of current valuation and strategic transformation. While total revenues declined 8% year-over-year in Q1 2025 ($13.72 billion), this largely reflects anticipated normalization as COVID-19 vaccines and treatments transition from pandemic to endemic status. Importantly, adjusted net income outperformed expectations, underlining operational discipline and resilience.

• Dividend Yield: At 7.19% forward, Pfizer offers one of the highest dividend yields in the blue-chip pharmaceutical universe—providing a compelling income stream, particularly relevant in a low-to-moderate interest rate environment.
• Valuation: The stock’s forward P/E of 8.14 and PEG ratio of 0.60 imply deep value both on a standalone and sector-relative basis. The price/sales (2.18) and price/book (1.54) metrics further emphasize the market’s underappreciation of Pfizer’s earnings power and asset base.
• Profitability: Despite top-line contraction, profit margin remains strong at 12.62%, with net income in excess of $7.8 billion TTM and robust cash flows supporting future investment and payout capacity.
• Strategic Expansion: Ongoing heavy investment in R&D and targeted acquisitions have expanded Pfizer’s pipeline, with notable growth in non-COVID franchises like Vyndaqel (rare disease), Ibrance (oncology), and Eliquis (cardiovascular), sustaining global market leadership.
• Cost Optimization: The rapid execution of a $7.7 billion cost alignment program is accelerating EPS recovery, driving operational leverage, and boosting competitive agility against peers.

Collectively, these elements point to a turnaround in profitability on more sustainable, diversified revenue streams—signaling an inflection point in Pfizer’s valuation cycle.

Volume and Liquidity

• Average 3-month daily volume of 52.63 million shares positions PFE among the most liquid equities on the NYSE, ensuring low spreads, reliable execution, and the ability for both institutional and retail investors to enter and exit positions efficiently.
• Current public float of 5.67 billion shares supports favorable dynamics for potential re-rating as positive news and catalysts materialize, without excessive dilution risk.

Such sustained turnover reflects ongoing institutional interest and sets the groundwork for dynamic price discovery, especially as fundamental and technical factors align.

Catalysts and Positive Outlook

• Pipeline Momentum: Multiple late-stage drugs are approaching key regulatory milestones, including next-generation vaccines and breakthrough therapies in rare diseases and oncology. These products are expected to start contributing meaningfully to revenues as early as late 2025.
• Operational Efficiency: Completion of the multi-billion-dollar cost-alignment program provides a durable margin cushion and positions Pfizer to redeploy resources into high-ROI innovation.
• Acquisition Strategy: Ongoing portfolio expansion through targeted M&A is enhancing Pfizer’s therapeutic breadth, supporting both medium- and long-term revenue growth.
• ESG Progress: Pfizer continues to lead on environmental, social, and governance (ESG) metrics within its peer group, attracting additional capital from funds with sustainability mandates.
• Dividend Stability: With a forward dividend yield above 7% and ample free cash flow, the payout appears sustainable—always a point of attraction in volatile markets.
• Secular Sector Tailwinds: Demographics (aging populations), rising global healthcare spending, and advancing biotechnological frontiers drive persistent demand for Pfizer’s innovations.

Should macro conditions remain stable and as the company converts its product pipeline into marketable therapies, these factors collectively underpin an optimistic scenario for earnings and share price appreciation through 2025 and beyond.

Investment Strategies

• Short-Term (Tactical plays):
• Recent support at ~$21.90 combined with an emerging uptrend above short-term moving averages encourages near-term entry strategies.
• With several potential newsflow catalysts (regulatory approvals, product launches) on the horizon, volatility-driven trades around earnings or pipeline events appear justified.
• Medium-Term (6-18 months):
• The stock’s trading range near multi-year lows, coupled with an improving cost structure and stabilizing core revenue base, argues for a “buy-on-dips” methodology through 2025.
• A close above $25.43 resistance (50-day SMA) could trigger notable follow-through buying, validating an intermediate trend reversal.
• Long-Term (Core holding):
• For dividend and value-oriented portfolios, Pfizer’s high yield, fortress balance sheet ($20+ billion in cash), and broad exposure to non-cyclical healthcare demand offer both stability and upside optionality.
• The ongoing pivot from COVID-centric revenues to new innovation cycles in oncology, rare diseases, and vaccines suggests attractive multi-year compounding potential as new launches mature.

Investors may consider scaling in at these levels, particularly with technical signals showing a bottoming process, and ahead of expected pipeline announcements or further upgrades to forward guidance.

Is it the Right Time to Buy Pfizer?

Summarizing the evidence, Pfizer’s investment case appears materially more attractive now than at any point over the last 18 months. Key strengths—compelling valuation (forward P/E of 8.1, PEG 0.60), sector-leading dividend income, de-risked balance sheet, and pipeline optionality—combine at precisely the moment the technical structure signals reversal from oversold territory. Rising institutional interest, paired with a clearly communicated margin improvement plan, has re-established confidence in the company’s ability to translate operational efficiency into earnings growth.

The consensus price target of $29.25 (22% upside) appears increasingly attainable given the convergence of cost discipline, portfolio diversification, and anticipated pipeline launches through 2025. With the healthcare sector set to benefit from secular trends and capital rotation, Pfizer seems to present an excellent opportunity for exposure to global pharmaceuticals at an attractive entry price.

In this favorable environment, the stock’s fundamentals justify renewed interest, and the technical setup suggests Pfizer may be entering a new bullish phase—making this blue-chip name worthy of close attention for investors seeking quality, yield, and innovation-driven upside as we look ahead to the recovery cycle in the healthcare sector.

How to buy Pfizer stock in United States?

Buying Pfizer stock online is both straightforward and secure when you go through a regulated broker in the United States. Today’s technology allows you to purchase shares in just a few clicks, whether you’re new to investing or looking to diversify your portfolio. You have two main options: directly buying Pfizer shares for long-term ownership (“spot buying”) or trading with Contracts for Difference (CFDs) for more flexible, short-term exposure. Each method has its features, risks, and cost structure—which we’ll explain step by step. If you’re wondering which brokers offer the best conditions, you’ll find a detailed comparison further down the page.

Spot Buying

When you buy Pfizer stock “for cash” or on the “spot market,” you become a direct owner of the shares, eligible to receive dividends and voting rights. This is the classic approach used by long-term investors. U.S.-based brokers usually charge a fixed commission per order, often between $0 and $10, depending on the platform.

Important example

For example, suppose Pfizer’s current share price is $23.93. If you invest $1,000 and the broker charges a $5 commission, you can buy approximately 41 shares [($1,000 – $5)/$23.93 ≈ 41].

✔️ Gain scenario: If Pfizer’s share price increases by 10%, your position would now be worth about $1,100.

Result: That’s a gross gain of $100, or +10% on your investment.

Trading via CFD

CFD trading means speculating on Pfizer’s share price movement—up or down—without owning the shares themselves. This method is often used for short-term trades and takes advantage of leverage, which multiplies both potential gains and losses. With CFDs, your main costs are the spread (the difference between buy/sell prices) and overnight financing fees if you hold positions open daily.

Important example

For example, with a $1,000 deposit and 5x leverage, you control an exposure of $5,000 to Pfizer shares.

✔️ Gain scenario: If Pfizer’s stock rises by 8%, your CFD position gains 8% x 5 = 40%.

Result: That’s a $400 gain on your $1,000 margin (excluding fees).

Final Advice

Before investing, it’s crucial to compare brokers’ fees, account features, leverage policies, and available investment tools—costs and conditions can vary widely. You’ll find a comprehensive broker comparator further down this page to help you make the best choice. Ultimately, whether you buy Pfizer shares for long-term holding or prefer the flexibility of CFDs depends on your investment goals and risk appetite. Take the time to review your options and choose the approach that’s right for you.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying Pfizer stock

The latest news about Pfizer

Pfizer’s stock has surged over 5% in the past week on strong Q1 2025 results and positive adjusted EPS. The company reported Q1 adjusted diluted EPS of $0.92, up 12% year-over-year and comfortably above analyst expectations, despite an 8% decline in revenue to $13.72 billion. The robust bottom-line performance was driven by operational efficiencies and cost-saving actions that offset declining COVID-19 related product sales. Management reaffirmed full-year 2025 guidance, signaling confidence in ongoing business stability. Market reaction in the United States was decidedly positive, with the stock showing notable short-term momentum as investors welcomed the earnings beat and continued commitment to profitability.

Pfizer’s cost alignment program now targets $7.7 billion in total savings, underpinning margin resilience and future profitability. CEO Albert Bourla announced an incremental $1.7 billion in cost cuts, bringing the cumulative savings target to nearly $8 billion. This substantial efficiency drive is aimed at neutralizing top-line pressure from normalization of pandemic-era product demand—especially relevant in the U.S. market, where ongoing operational improvements are considered crucial for maintaining profit margins amid a more competitive and regulation-sensitive environment. The success of these measures is reflected in the improved adjusted EPS and maintained dividend payout levels, reinforcing investor confidence in Pfizer’s capacity to defend shareholder returns.

Pfizer continues to deliver a highly attractive dividend yield of 7.19%, appealing to U.S. income-focused investors. With an ex-dividend date set for May 9, 2025, and a quarterly dividend of $0.43 per share, Pfizer offers one of the highest yields among large-cap U.S. healthcare stocks. The substantial dividend is supported by a solid cash position ($20.48 billion) and recurring revenue from a diversified product portfolio, including core U.S. franchises such as Prevnar 13, Ibrance, and Eliquis. The steady income stream remains a key differentiator, particularly in a market climate characterized by macroeconomic uncertainty and the search for reliable yield.

Pfizer’s U.S.-centric growth strategy targets pipeline productivity and expansion in rare disease and oncology solutions. Despite the ongoing industry-wide pivot away from COVID-19 products, recent drug launches—most notably Vyndaqel for amyloidosis—have gained traction, underpinning hopes for resiliency and renewed top-line growth. Management emphasizes investments in R&D for high-value therapeutic areas tailored to the needs of U.S. patients and payers, suggesting a forward-looking focus on innovative, market-relevant treatments that could offset future patent expirations and competitive headwinds.

Analyst consensus anticipates significant potential upside, with a price target implying approximately 22% growth from current levels. While longer-term technical indicators show the stock remains below key averages, the consensus target price of $29.25 reflects optimism regarding sustained earnings recovery, the effectiveness of cost control, and the value of a robust dividend. Major Wall Street firms highlight Pfizer’s stable fundamentals, seasoned management, and global scale, but especially note the constructive market reaction in the United States as a sign the stock’s risk-reward profile may be shifting favorably for both income and value-oriented investors.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.